Advanced cutaneous malignant melanoma: A systematic review of economic and quality-of-life studies

Value in Health

Volumn 11, Issue 2, 2008, Pages 259-271

  Cashin, Richard P ^a   Lui, Philip ^a   Machado, Márcio ^a,b   Hemels, Michiel E H ^c   Corey Lisle, Patricia K ^c   Einarson, Thomas R ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CHILE   (Chile)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Advanced malignant melanoma; Pharmacoeconomics; Quality of life; Systematic review

Indexed keywords

CYTOKINE; DACARBAZINE; FOTEMUSTINE; HISTAMINE; INTERFERON; TEMOZOLOMIDE;

ADVANCED CANCER; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG COST; ECONOMIC EVALUATION; HUMAN; MELANOMA; METASTASIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW;

EID: 41549138289     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00243.x     Document Type: Article

References (33)

1. Surveillance Research Program, Cancer Statistics Branch. Surveillance, Epidemiology, and End Results (SEER) Program. Washington, DC : National Cancer Institute, 2005.
2. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004 150 : 179 85.
3. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998 83 : 1664 78.
4. Crosby T, Fish R, Coles B, Mason MD. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2000 CD001215.
5. Barth A, Wanek LA, Morton DL. Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg 1995 181 : 193 201.
6. Eton O, Legha SS, Moon TE, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998 16 : 1103 11.
7. Crott R. Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma. Pharmacoeconomics 2004 22 : 569 80.
8. Balch CM, Buzaid AC, Atkins MB, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000 88 : 1484 91.
9. Iskedjian M, Trakas K, Bradley CA, et al. Quality assessment of economic evaluations published in PharmacoEconomics. The first four years (1992 to 1995). Pharmacoeconomics 1997 12 : 685 94.
10. Crott R, Ali F, Burdette-Radoux S. Cost-utility of adjuvant high-dose interferon alpha therapy in Stage III cutaneous melanoma in Quebec. Value Health 2004 7 : 423 32.
11. Hillner BE, Agarwala S, Middleton MR. Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma. J Clin Oncol 2000 18 : 1474 80.
12. Agnese DM, Abdessalam SF, Burak WE Jr., et al. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery 2003 134 : 542 7.
13. Hoffmann U, Szedlak M, Tittgen W, et al. Primary staging and follow-up in melanoma patients - monocenter evaluation of methods, costs and patient survival. Br J Cancer 2002 87 : 151 7.
14. Mooney MM, Mettlin C, Michalek AM, et al. Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences. A cost-effectiveness analysis. Cancer 1997 70 : 1052 64.
15. Guidelines for the evaluation of health technologies (3rd ed.). Ottawa : Canadian Agency for Drugs and Technologies in Health, 2006.
16. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004 15 (22 1118 25.
17. Beusterien KM, Ackerman SJ, Plante K, et al. The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma. Support Care Cancer 2003 11 : 304 12.
18. Brown JE, Brown RF, Miller RM, et al. Coping with metastatic melanoma: the last year of life. Psychooncology 2000 9 : 283 92.
19. Butow PN, Coates AS, Dunn SM. Psychosocial predictors of survival in metastatic melanoma. J Clin Oncol 1999 17 : 2256 63.
20. Coates A, Thomson D, McLeod GR, et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer 1993 29A : 1731 4.
21. Cohen L, Parker PA, Sterner J, De Moor C. Quality of life in patients with malignant melanoma participating in a phase I trial of an autologous tumor-derived vaccine. Melanoma Res 2002 12 : 505 11.
22. Kiebert GM, Jonas DL, Middleton MR. Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest 2003 21 : 821 9.
23. Ridolfi R, Chiarion-Sileni V, Guida M, et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002 20 : 1600 7.
24. Sigurεardottir V, Bolund C, Brandberg Y, Sullivan M. The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique. Qual Life Res 1993 2 : 193 203.
25. Sigurεardottir V, Bolund C, Nilsson B. Quality of life and ethics: opinions about chemotherapy among patients with advanced melanoma, next of kin and care-providers. Psychooncology 1995 4 : 287 300.
26. Sigurεardottir V, Bolund C, Sullivan M. Quality of life evaluation by the EORTC questionnaire technique in patients with generalized malignant melanoma on chemotherapy. Acta Oncol 1996 35 : 149 58.
27. Sigurεardottir V, Brandberg Y, Sullivan M. Criterion-based validation of the EORTC QLQ-C36 in advanced melanoma: the CIPS questionnaire and proxy raters. Qual Life Res 1996 5 : 375 86.
28. Young AM, Marsden J, Goodman A, et al. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol (R Coll Radiol) 2001 13 : 458 65.
29. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000 18 : 158 66.
30. Thomson DB, Adena M, McLeod GR, et al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res 1993 3 : 133 8.
31. Tengs TO. Cost-effectiveness versus cost-utility analysis of interventions for cancer: does adjusting for health-related quality of life really matter? Value Health 2004 7 : 70 8.
32. Bradley CA, Iskedjian M, Lanctôt KL, et al. Quality assessment of economic evaluations in selected pharmacy, medical, and health economics journals. Ann Pharmacother 1995 29 : 681 9.
33. Machado M, Iskedjian M, Einarson TR. Quality assessment of published health economic analyses from South America. Ann Pharmacother 2006 40 : 943 9.